云顶新耀(01952)获Dimerix授予独家许可在大中华区、韩国及若干东南亚国家开发及商业化DMX-200

智通财经06-16

智通财经APP讯，云顶新耀(01952)公布，于2026年6月16日，公司与Dimerix Limited(一家于澳洲证券交易所上市的公司，股份代号：DXB)订立协议，据此，Dimerix不可撤销地向公司授予一项独家许可，以在大中华区、韩国及若干东南亚国家开发及商业化DMX-200。DMX-200是一种趋化因子受体2(CCR2)的小分子抑制剂，目前正在进行针对局灶节段性肾小球硬化症(局灶节段性...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2643412781?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-16 06:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643412781","market":"us","top_or_hot":-1,"title":"云顶新耀(01952)获Dimerix授予独家许可在大中华区、韩国及若干东南亚国家开发及商业化DMX-200","media":"智通财经","content":"<div>\n<p>智通财经APP讯，云顶新耀(01952)公布，于2026年6月16日，公司与Dimerix Limited(一家于澳洲证券交易所上市的公司，股份代号：DXB)订立协议，据此，Dimerix不可撤销地向公司授予一项独家许可，以在大中华区、韩国及若干东南亚国家开发及商业化DMX-200。DMX-200是一种趋化因子受体2(CCR2)的小分子抑制剂，目前正在进行针对局灶节段性肾小球硬化症(局灶节段性...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1454717.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>云顶新耀(01952)获Dimerix授予独家许可在大中华区、韩国及若干东南亚国家开发及商业化DMX-200</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n云顶新耀(01952)获Dimerix授予独家许可在大中华区、韩国及若干东南亚国家开发及商业化DMX-200\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-16 06:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1454717.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，云顶新耀(01952)公布，于2026年6月16日，公司与Dimerix Limited(一家于澳洲证券交易所上市的公司，股份代号：DXB)订立协议，据此，Dimerix不可撤销地向公司授予一项独家许可，以在大中华区、韩国及若干东南亚国家开发及商业化DMX-200。DMX-200是一种趋化因子受体2(CCR2)的小分子抑制剂，目前正在进行针对局灶节段性肾小球硬化症(局灶节段性...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1454717.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1454717.html","article_id":"2643412781","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643412781","pubTimestamp":1781564298,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，云顶新耀 公布，于2026年6月16日，公司与Dimerix Limited订立协议，据此，Dimerix不可撤销地向公司授予一项独家许可，以在大中华区、韩国及若干东南亚国家开发及商业化DMX-200。DMX-200是一种趋化因子受体2的小分子抑制剂，目前正在进行针对局灶节段性肾小球硬化症的关键性临床3期研究ACTION3。DMX-200已获得美国食品药品监督管理局及欧洲药品管理局的孤儿药资格认定。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1583":"高瓴概念","BK1161":"生物科技","DMX":"DoubleLine Multi-Sector Income ETF","01952":"云顶新耀"},"translate_title":"Genting Xinyao (01952) was granted an exclusive license by Dimerix to develop and commercialize DMX-200 in Greater China, Korea and certain Southeast Asian countries","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DMX":1.5,"01952":1.5},"content_text":"智通财经APP讯，云顶新耀(01952)公布，于2026年6月16日，公司与Dimerix Limited(一家于澳洲证券交易所上市的公司，股份代号：DXB)订立协议，据此，Dimerix不可撤销地向公司授予一项独家许可，以在大中华区、韩国及若干东南亚国家开发及商业化DMX-200。DMX-200是一种趋化因子受体2(CCR2)的小分子抑制剂，目前正在进行针对局灶节段性肾小球硬化症(局灶节段性肾小球硬化症)的关键性临床3期研究ACTION3。DMX-200已获得美国食品药品监督管理局(FDA)及欧洲药品管理局(EMA)的孤儿药资格认定。根据该独家许可，公司的付款义务包括：(i)首付款1000万美元;及(ii)潜在的开发及监管里程碑付款，最高可达3000万美元;(iii)潜在的销售里程碑付款，最高可达3亿美元;及(iv)基于未来年度净销售额的潜在分层特许权使用费，在10%至15%之间。公告称，是次交易预期将进一步强化公司的肾病产品组合及管线协同效应，巩固公司在肾脏及自身免疫性疾病领域的战略地位。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643412781","isCrawlerRequest":true}